%20Co.%2C%20Ltd./other/PharmaResources_Shanghai_Co._Ltd.-logo.png)
PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings
PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 北京市嘉源律师事务所关于上海泓博智源医药股份有限公司2025年年度股东会的法律意见书 | 2026-05-19 | Chinese | |
| 2025年年度股东会决议公告 | 2026-05-19 | Chinese | |
| 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导定期现场检查报告 | 2026-05-18 | Chinese | |
| 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导培训情况的报告 | 2026-05-18 | Chinese | |
| 中信证券股份有限公司关于上海泓博智源医药股份有限公司持续督导保荐总结报告书 | 2026-05-18 | Chinese | |
| 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度跟踪报告 | 2026-05-18 | Chinese |
Browse filings by year
5 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46534700 | 北京市嘉源律师事务所关于上海泓博智源医药股份有限公司2025年年度股东会的法律意见书 | 2026-05-19 | Chinese | ||
| 46534704 | 2025年年度股东会决议公告 | 2026-05-19 | Chinese | ||
| 46384983 | 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导定期现场检查报告 | 2026-05-18 | Chinese | ||
| 46384981 | 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导培训情况的报告 | 2026-05-18 | Chinese | ||
| 46384980 | 中信证券股份有限公司关于上海泓博智源医药股份有限公司持续督导保荐总结报告书 | 2026-05-18 | Chinese | ||
| 46384979 | 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度跟踪报告 | 2026-05-18 | Chinese | ||
| 46350313 | 关于举行2025年度网上业绩说明会的公告 | 2026-05-15 | Chinese | ||
| 40012741 | 第四届董事会第七次会议决议公告 | 2026-04-28 | Chinese | ||
| 40012736 | 2024年限制性股票激励计划授予价格调整、第一个归属期归属条件成就及部分限制性股票作废相关事项的法律意见书 | 2026-04-28 | Chinese | ||
| 40012727 | 2026年一季度报告 | 2026-04-28 | Chinese | ||
| 40012714 | 2025年年度审计报告 | 2026-04-28 | Chinese | ||
| 40012695 | 2025年年度报告摘要 | 2026-04-28 | Chinese | ||
| 40012688 | 关于调整2024年限制性股票激励计划授予价格的公告 | 2026-04-28 | Chinese | ||
| 40012683 | 2025年度董事会工作报告 | 2026-04-28 | Chinese | ||
| 40012671 | 2025年度独立董事述职报告 (尤启冬) | 2026-04-28 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
PharmaResources (Shanghai) Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56163/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56163 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56163 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56163 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56163}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PharmaResources (Shanghai) Co., Ltd. (id: 56163)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.